Norgine B.V. announces appointment of Alan Butcher as Chief Corporate Development Officer

28 March 2022

Norgine B.V. announces appointment of
Alan Butcher as Chief Corporate Development Officer

AMSTERDAM, The Netherlands, 28 March 2022. Norgine B.V. (Norgine), a leading European specialist pharmaceutical company, today announces that Alan Butcher has been appointed Chief Corporate Development Officer.

Alan joins Norgine’s Executive Committee and will be responsible for all Corporate Development activity, with a focus on in-licensing European and Australia/New Zealand (“ANZ”) rights to innovative pipeline products, as well as M&A. Alan will be based in the United States, where he will focus on deepening Norgine’s relationships with North American corporates and investors.

Christopher Bath, Chief Executive Officer of Norgine, commented: “I am delighted to welcome Alan to Norgine. He joins us in this critical role at an exciting stage in Norgine’s development, as we look to accelerate our Corporate Development efforts and bring more medicines to more patients across Europe and ANZ more quickly. I have no doubt that Alan will bring tremendous value to Norgine and our patients through his scientific knowledge, commercial acumen and deep relationships across the sector.”

Alan Butcher said: “I look forward to working with Chris and the Norgine team. I have been impressed by Norgine’s commitment to patients and the ambition to grow through in-licensing and M&A. I am confident that as the business continues through its enterprise-wide Transformation Programme, we will be able to meet our growth expectations and deliver real value to patients and healthcare systems.”

Alan brings extensive strategic, business development, technical and scientific experience to Norgine from over 30 years in the pharmaceutical industry. He joins Norgine from Lupin Limited (“Lupin”), where he served as Chief Corporate Development Officer. Prior to Lupin, he served as Executive Vice President and Chief Business Officer for AMAG Pharmaceuticals. Prior to AMAG, he held senior management roles at Purdue Pharma, Shire Pharmaceuticals, and Endo.  Alan also held business development roles at Bristol Myers Squibb and GlaxoSmithKline.  Earlier in his career, he conducted scientific research in areas of molecular genetics, virology and cardiovascular drug discovery.

Alan holds a Bachelor of Science in Clinical Microbiology and a Master of Arts in Biology with a concentration in Molecular Biology and Genetics from West Chester University of Pennsylvania. He is also an MBA graduate from Cornell University’s Johnson Graduate School of Management.



For further information please contact:

Eleni Fistikaki +44 (0)1895826227 or +44 (0)7825 389477

Follow us @norgine


Notes to Editors:

About Norgine

Norgine is a leading European specialist pharmaceutical company that has been bringing transformative medicines to patients for over a century. Our commitment to transforming people’s lives drives everything we do and our European experience, fully integrated infrastructure and exceptional partnership approach enables us to quickly apply creative solutions to bring life-changing medicines to patients that they may not otherwise be able to access. Norgine is proud to have helped 24 million patients around the world in 2021 and generated €505 million in net product sales, representing growth of 10% over 2020.

Norgine has a direct presence in 16 European countries, as well as Australia and New Zealand. We also have a strong global network of partnerships in non-Norgine markets. We are a flexible and fully integrated pharmaceutical business, with manufacturing (Hengoed, Wales and Dreux, France), third party supply networks and significant product development capabilities, in addition to our sales and marketing infrastructure. This enables us to acquire, develop and commercialise specialist and innovative products that make a real difference to the lives of patients around the world.

NORGINE and the sail logo are trademarks of the Norgine group of companies.